Antibodies Contract Manufacturing Market Worth $35.9 Billion by 2030: Grand View Research, Inc.

SAN FRANCISCO, April 26, 2022 /PRNewswire/ -- The global antibodies contract manufacturing market is expected to reach USD 35.9 billion by 2030, registering a CAGR of 13.1% from 2022 to 2030, according to a new report by Grand View Research, Inc. Rise in demand for the production of therapeutic antibodies is the main factor that will drive the growth of the market during the forecast period. Antibodies are the leading biopharmaceutical products that precisely target abnormal cells. Thus, many biopharmaceutical companies have begun to focus on the development of advanced antibodies for the treatment of chronic diseases such as cancer, arthritis, and rheumatic heart disease. The impact of COVID-19 has boosted the market growth, with the application of monoclonal antibodies therapy used as a treatment for COVID-19 patients.

Key Insights & Findings from the report:

• Monoclonal antibodies-based antibody contract manufacturing captured the largest market share about 70.9% in 2021, owing to the high penetration of mammalian expression systems for biologics development.
• Based on the source offered in this market, the mammalian segment contributed the largest share of 58.5% in 2021, as they are considered a more reliable, robust, and relatively mature technology.
• Asia Pacific is expected to emerge as the fastest-growing regional market with a CAGR of 13.3% from 2022 to 2030, owing to developing economies such as India, South Korea, and China incorporating developments to sustain the competition.

Read 100 page market research report, "Antibodies Contract Manufacturing Market Size, Share & Trends Analysis Report, By Product (Monoclonal Antibodies, Polyclonal Antibodies, Others), By Source, By End Use, By Region, And Segment Forecasts, 2022 - 2030", published by Grand View Research.

Antibodies Contract Manufacturing Market Growth & Trends

A surge in the R&D budget for the production of antibodies by key players is also driving the growth of the market. For the ongoing fight against COVID-19, Monoclonal antibody (mAb) therapy is proven to be an effective treatment. The aim of this treatment is to prevent hospitalizations, decrease viral loads, and minimize symptom severity.

During the coronavirus outburst, the supply chain of biopharmaceutical companies remained robust and was largely unaffected worldwide. Similarly, antibody contract manufacturers are observing a rise in demand for the production of antibodies that will be used for treatments related to the COVID-19 vaccine and therapeutics. Thus, the future holds numerous opportunities for the antibody contract manufacturing market. For instance, in December 2021, an agreement was formed between Samsung Biologics and AstraZeneca to manufacture Evusheld, which is an amalgamation of binary antibodies in development for the potential treatment of COVID-19.

The growth of CMOs is greatly dependent on favorable opportunities offered by the biopharmaceutical industry. Expansion and increasing robustness of venture capital investments for the life science sector are two important opportunities that are anticipated to drive the market. For instance, in 2022, FUJIFILM Diosynth Biotechnologies announced an expansion in North Carolina; with this expansion, the company will increase skilled positions including researchers and scientists by 2024 to generate strong commercial processes

Antibodies Contract Manufacturing Market Segmentation

Grand View Research has segmented the global antibodies contract manufacturing market based on product, source, end-user, and region:

Antibodies Contract Manufacturing Product Outlook (Revenue, USD Million, 2017 - 2030)

• Monoclonal Antibodies
• Polyclonal Antibodies
• Others

Antibodies Contract Manufacturing Source Outlook (Revenue, USD Million, 2017 - 2030)

• Mammalian
• Microbial

Antibodies Contract Manufacturing End User Outlook (Revenue, USD Million, 2017 - 2030)

• Biopharmaceutical Companies
• Research Laboratories
• Others

Antibodies Contract Manufacturing Regional Outlook (Revenue, USD Million, 2017 - 2030)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Chile
• Middle East & Africa
• South Africa
• UAE
• Egypt

 List of Key Players in the Antibodies Contract Manufacturing Market

• Lonza
• Samsung Biologics
• WuXi Biologics.
• Charles River Laboratories
• FUJIFILM Holdings Corporation
• Boehringer Ingelheim Biopharmaceuticals GmbH.
• AGC Biologics
• Cytovance Biologics, Inc.
• EMERGENT
• Thermo Fisher Scientific
• Labcorp Drug Development
• Catalent, Inc.

Check out more related studies published by Grand View Research:

• Healthcare Contract Development And Manufacturing Organization Market - The global healthcare contract development and manufacturing organization market size is anticipated to reach USD 388.3 billion by 2028, expanding at a CAGR of 8.6%, according to a new report by Grand View Research, Inc. Increasing outsourcing of R&D is one of the major factors contributing to the market growth.
• Medical Device Contract Research Organization Market - The global medical device contract research organization market size is expected to reach USD 12.1 billion by 2028, registering a CAGR of 8.6% over the forecast period, according to a new report by Grand View Research, Inc. During the second half of the COVID-19 pandemic in 2020, the market witnessed a surge in demand for CRO services as compared to the first half, where the growth was stagnant. The main driver of the market includes time-saving, cost efficiency, and expertise in the area, which accelerates the process of devices reaching the market. In addition, outsourcing to a CRO with precise expertise in a medical device helps in meeting the complex regulatory requirements and audits as they work on it on a daily basis.
• Healthcare Contract Research Organization Market - The global healthcare contract research organization market size is expected to reach USD 74.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.5% from 2022 to 2030. The increasing cost of drug development is expected to drive market demand over the forecast period. Also, rising clinical trial costs and challenges pertaining to patient recruitment have led biopharmaceutical companies to turn to regions like Central and Eastern Europe, Asia Pacific, Latin America, and the Middle East for cost savings and quick patient recruitment.

Browse through Grand View Research's Medical Devices Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Grand View Compass | Grand View Pipeline
Follow Us: LinkedIn | Twitter

SOURCE Grand View Research, Inc.